Frontlight ResearchEarly access
Amyloidosis trials in Portugal
8 of 14 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleTRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Where
- Carnaxide, Guimaraes, Leiria, Lisbon, Vila Real, Viseu
- Age
- 18 years to 85 years
- People
- 2,250 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07052903 · EU 2024-519917-72-00 - Phase 3Taking peopleMAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
- Where
- Lisbon
- Age
- 18 years to 90 years
- People
- 1,200 worldwide
- Run by
- Intellia Therapeutics
See details and how to joinNCT06128629 · EU 2023-507220-23-00 - Phase 3Enrolling by invitationA Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Where
- Creixomil, Lisbon, Porto, Viseu
- Age
- 18 years and over
- People
- 700 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT06679946 - Phase 3Active, not recruitingTRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
- Where
- Lisboa, Porto
- Age
- 18 years to 85 years
- People
- 125 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07223203 · EU 2025-522544-40-00 - Phase 3Not yet taking people in PortugalTo Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
- Where
- Lisbon, Porto
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT07116473 · EU 2024-513676-18-00 - Phase 3Taking peopleAcoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- Where
- Lisbon, Porto
- Age
- 18 years to 75 years
- People
- 587 worldwide
- Run by
- Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT06563895 · EU 2024-513547-82-00 - Phase 3Enrolling by invitationAn Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
- Where
- Guimarães, Lisbon, Porto
- Age
- 18 years and over
- People
- 1,400 worldwide
- Run by
- Ionis Pharmaceuticals, Inc.
See details and how to joinNCT05667493 - No phaseTaking peopleExercise in Hereditary ATTR (ATTRv) Amyloidosis
- Where
- Maia
- Age
- 18 years and over
- People
- 42
- Run by
- University of Maia
See details and how to joinNCT07033715